Top

Published in:

01-12-2019 | Case Report

Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report

Authors: Matthew Michael Sochat, Jinhua Piao, Nishant Poddar

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Excerpt

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second most common cause of cancer-related mortality worldwide. Higher prevalence is seen in Asia and other developing countries [1]. Both the incidence and the mortality from this cancer are increasing in the USA [2]. Metastasis to the orbit is rare in hepatocellular carcinoma, with infrequent mention in the literature to date [3‐5]. Approximately 50% of these unusual cases represent the initial diagnosis of metastatic disease. …

Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Globcan 2008 v2. 0. Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. Lyon, France. International Agency for Research on Cancer. 2010, Accessed: May 5th, 2018: http://globocan.iarc.fr.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed

Gupta R, Honavar SG, Vemuganti GK. Orbital metastasis from hepatocellular carcinoma. Surv Ophthalmol. 2005;50:485–9. https://doi.org/10.1016/j.survophthal.2005.06.014.CrossRefPubMed

Eldesouky MA, Elbakary MA, Shalaby OE, Shareef MM. Orbital metastasis from hepatocellular carcinoma: report of 6 cases. Ophthalmic Plast Reconstr Surg. 2014;30:78–82. https://doi.org/10.1097/IOP.0b013e31829f3a57.CrossRef

Quick AM, Bloomston M, Kim EY, Hall NC, Mayr NA. Complete response to radiation therapy of orbital metastasis from hepatocellular carcinoma. World J Gastroenterol: WJG. 2009;15:6000–3. https://doi.org/10.3748/wjg.15.6000.CrossRefPubMedPubMedCentral

Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139:1534–45. https://doi.org/10.1002/ijc.30211.CrossRefPubMedPubMedCentral

Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122:1757–65. https://doi.org/10.1002/cncr.29971.CrossRefPubMed

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80. https://doi.org/10.1002/hep.29086.CrossRefPubMed

Zhang B-H, Yang B-H, Tang Z-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22. https://doi.org/10.1007/s00432-004-0552-0.CrossRefPubMed

10.

Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines from 2001 to 2017. Bioscience Trends. 2017;11:389–98. https://doi.org/10.5582/bst.2017.01202.CrossRefPubMed

11.

Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6. https://doi.org/10.1093/cid/cit234.CrossRefPubMed

12.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2013;58:495–501. https://doi.org/10.1016/j.jhep.2012.10.017.CrossRefPubMed

13.

Kim S, Chun M, Wang H, Cho S, Oh YT, Kang SH, et al. Bone metastasis from primary hepatocellular carcinoma: characteristics of soft tissue formation. Cancer Res Treat. 2007;39:104–8. https://doi.org/10.4143/crt.2007.39.3.104.CrossRefPubMedPubMedCentral

14.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMed

15.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMed

16.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.CrossRefPubMed

17.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2.CrossRefPubMedPubMedCentral

Title: Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report
Authors: Matthew Michael Sochat
Jinhua Piao
Nishant Poddar
Publication date: 01-12-2019
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-018-0159-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Two Sessions of Radiotherapy Were Successful in Treating Gastric Cancer with Bleeding

Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience

Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran

Laparoscopic Liver Resection in a Case of Asymptomatic Elderly Patient with Caroli Syndrome

Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer

Undifferentiated Embryonal Sarcoma of the Liver: a Great Masquerader

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page